Kuo Fu-Feng Discloses Investment at Jyong Biotech with 33.34% Stake

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Ms. Kuo Fu-Feng disclosed a 33.34% stake in Jyong Biotech Ltd. through a Schedule 13D filing. The filing, dated April 24, 2026, details ownership through Perfect Minds Co., Ltd. and related trust entities. The position gives Kuo meaningful influence, as she also serves as Jyong Biotech’s CEO and Chairwoman.

Investor Intent

Kuo states she holds the shares for investment purposes and does not outline plans for actions like mergers, board changes, buybacks, or asset sales. The filing makes no commitments to specific strategic or governance moves at this time.

She exercises sole voting and dispositive power over the 25,349,500 shares held by Perfect Minds Co., Ltd., but she does not set any ownership caps or timelines for future actions. The group also disclaims that it forms a Section 13(d) “group,” except as expressly stated.

Investor's Background

Ms. Kuo Fu-Feng is the Chief Executive Officer and Chairwoman of Jyong Biotech Ltd. She is the settlor of The Innovation Trust and the sole director of Perfect Minds Co., Ltd., which directly holds the reported shares. Her investment approach here centers on a strategic, long-term stake in the company she leads.

Original SEC Filing: Jyong Biotech Ltd. [ MENS ] - SCHEDULE 13D - Apr. 24, 2026

Disclaimer
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

Source: TradingView The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.